Allakos Inc. (ALLK) NASDAQ
0.33
+0.0007(+0.22%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.33
+0.0007(+0.22%)
Currency In USD
| Previous Close | 0.33 |
| Open | 0.33 |
| Day High | 0.33 |
| Day Low | 0.33 |
| 52-Week High | 1.56 |
| 52-Week Low | 0.22 |
| Volume | 1.31M |
| Average Volume | 2.85M |
| Market Cap | 29.74M |
| PE | -0.42 |
| EPS | -0.78 |
| Moving Average 50 Days | 0.27 |
| Moving Average 200 Days | 0.74 |
| Change | 0 |
Data not available
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
GlobeNewswire Inc.
Apr 02, 2025 12:00 PM GMT
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it h
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
GlobeNewswire Inc.
Jan 27, 2025 12:00 PM GMT
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 06, 2024 9:02 PM GMT
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business updat